Loading...
XNAS
INDP
Market cap7mUSD
Jul 09, Last price  
12.87USD
1D
9.35%
1Q
2,581.25%
Jan 2017
-97.18%
IPO
-97.32%
Name

Indaptus Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
85.83%
Rev. gr., 5y
%
Revenues
0k
Net income
-15m
L-2.60%
-7,176,943-13,362,000-28,909,000-43,543,000-47,599,000-3,569,037-7,693,664-13,734,690-15,423,471-15,022,027
CFO
-12m
L-8.07%
-7,926,450-12,005,000-22,132,000-39,076,000-29,045,000-3,324,628-11,290,535-13,078,347-13,405,315-12,323,188

Profile

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
URL
https://indaptusrx.com/
IPO date
Sep 07, 2012
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
15,366
16,378
14,911
Unusual Expense (Income)
NOPBT
(15,366)
(16,378)
(14,911)
NOPBT Margin
Operating Taxes
(588)
Tax Rate
NOPAT
(15,366)
(16,378)
(14,323)
Net income
(15,022)
-2.60%
(15,423)
12.30%
(13,735)
78.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,511
BB yield
-69.95%
Debt
Debt current
84
203
80
Long-term debt
84
248
80
Deferred revenue
Other long-term liabilities
1,459
Net debt
(5,618)
(12,910)
(26,272)
Cash flow
Cash from operating activities
(12,323)
(13,405)
(13,078)
CAPEX
(173)
Cash from investing activities
17,141
(16,427)
Cash from financing activities
4,748
FCF
(15,274)
(16,471)
(14,231)
Balance
Cash
5,787
13,362
26,433
Long term investments
Excess cash
5,787
13,362
26,433
Stockholders' equity
(60,319)
(45,333)
(29,813)
Invested Capital
64,348
57,686
54,395
ROIC
ROCE
EV
Common stock shares outstanding
9,356
8,401
8,262
Price
0.84
-52.15%
1.76
21.38%
1.45
-74.56%
Market cap
7,878
-46.72%
14,786
23.42%
11,980
-48.62%
EV
2,260
1,876
(14,292)
EBITDA
(15,365)
(16,377)
(14,909)
EV/EBITDA
0.96
Interest
588
Interest/NOPBT